NBI-74330
NBI-74330 is a potent antagonist for CXCR3, and exhibits potent inhibition of (125I) CXCL10 and (125I) CXCL11 specific binding with Ki of 1.5 and 3.2 nM, respectively.
Product Specifications
CAS Number
855527-92-3
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CXCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Endocrinology
Assay Protocol
https://www.medchemexpress.com/NBI-74330.html
Purity
99.76
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N([C@@H](C1=NC2=NC=CC=C2C(N1C3=CC=C(OCC)C=C3)=O)C)CC4=CC=CN=C4)CC5=CC=C(F)C(C(F)(F)F)=C5
Molecular Formula
C32H27F4N5O3
Molecular Weight
605.58
Precautions
H302, H315, H319, H335
References & Citations
[1]Heise CE, et al. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther. 2005 Jun;313 (3) :1263-71.|[2]Jopling LA, et al. Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay. Br J Pharmacol. 2007 Dec;152 (8) :1260-71.|[3]van Wanrooij EJ, et al. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2008 Feb;28 (2) :251-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CXCR3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC941680-500 1x 500 µL
CD45RA (Leukocyte Marker) (K4B5), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680102-500 1x 500 µL
Golgi Complex (371-4), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details